Welcome to our dedicated page for Neurobo Pharmaceuticals SEC filings (Ticker: NRBO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NeuroBo Pharmaceuticals Inc. filings, under the MetaVia Inc. registrant name after its name change, document a clinical-stage biotechnology issuer centered on cardiometabolic drug development. Recent Form 8-K disclosures include quarterly results and corporate updates, Regulation FD materials, corporate presentations, and press releases related to DA-1726 for obesity and DA-1241 for MASH.
The filing record also covers stockholder-meeting matters, including director elections, auditor ratification, executive-compensation advisory votes, reverse stock-split authorization proposals, Nasdaq share-issuance proposals, and common stock voting mechanics. These disclosures frame the company's governance, capital structure, clinical-development communications, and Exchange Act reporting obligations.